Junshi Biosciences and Antengene to Evaluate JS207 with ATG-037 in Combination Therapy
Junshi Biosciences and Antengene announced a strategic collaboration to evaluate the combination of JS207 (a PD-1/VEGF bispecific antibody) and ATG-037 (an oral CD73 inhibitor). Prior data presented at Antengene's R&D Day showed ATG-037 plus anti-PD-1 therapy produced responses in checkpoint inhibitor–resistant melanoma and NSCLC, with an acceptable safety profile reported.
